These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15199074)

  • 61. Vestibulotoxicity: a risk of home aminoglycoside therapy.
    Saunders JE
    J Okla State Med Assoc; 2005 Dec; 98(12):596-600. PubMed ID: 16425609
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aminoglycosides: a practical review.
    Gonzalez LS; Spencer JP
    Am Fam Physician; 1998 Nov; 58(8):1811-20. PubMed ID: 9835856
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aminoglycoside utilization study.
    Haslett TM; Reynolds JR
    Hosp Pharm; 1988 Oct; 23(10):872, 874-5, 878-80. PubMed ID: 10290108
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Commentary: once-daily aminoglycoside dosing: where are we now?
    Martin JE
    J Crit Care; 2003 Jun; 18(2):113-4. PubMed ID: 12800121
    [No Abstract]   [Full Text] [Related]  

  • 66. Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing.
    Toschlog EA; Blount KP; Rotondo MF; Sagraves SG; Bard MR; Schenarts PJ; Swanson M; Goettler CE
    J Trauma; 2003 Aug; 55(2):255-60; discussion 260-2. PubMed ID: 12913634
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Glomerular nephrotoxicity of aminoglycosides.
    Martínez-Salgado C; López-Hernández FJ; López-Novoa JM
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):86-98. PubMed ID: 17602717
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: A Case Presentation and Review of the Literature.
    Samaniego-Picota MD; Whelton A
    Am J Ther; 1996 Mar; 3(3):248-257. PubMed ID: 11862257
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service.
    Pinilla J; Shafran S; Conly J
    Clin Invest Med; 1992 Feb; 15(1):8-17. PubMed ID: 1572110
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Aminoglycoside-associated nephrotoxicity in the elderly.
    Baciewicz AM; Sokos DR; Cowan RI
    Ann Pharmacother; 2003 Feb; 37(2):182-6. PubMed ID: 12549943
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital.
    Nicolau DP; Belliveau PP; Nightingale CH; Quintiliani R; Freeman CD
    Hosp Pharm; 1995 Aug; 30(8):674-6, 679-80. PubMed ID: 10144645
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
    Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
    Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of cyclosporine nephrotoxicity with aminoglycoside nephrotoxicity.
    Bennett WM
    Clin Nephrol; 1986; 25 Suppl 1():S126-9. PubMed ID: 3519022
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination.
    Bookstaver PB; Johnson JW; McCoy TP; Stewart D; Williamson JC
    Ann Pharmacother; 2008 Dec; 42(12):1758-65. PubMed ID: 19047358
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review.
    Stabler SN; Ensom MH
    Can J Hosp Pharm; 2011 May; 64(3):182-91. PubMed ID: 22479053
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Is it possible to reduce the incidence of aminoglycoside-induced nephrotoxicity?].
    Fillastre JP
    Bull Acad Natl Med; 1999; 183(5):973-82; discussion 983. PubMed ID: 10465001
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aminoglycoside-induced nephrotoxicity in children.
    McWilliam SJ; Antoine DJ; Smyth RL; Pirmohamed M
    Pediatr Nephrol; 2017 Nov; 32(11):2015-2025. PubMed ID: 27848094
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical assessment of a published model to predict aminoglycoside-induced nephrotoxicity.
    Garrison MW; Rotschafer JC
    Ther Drug Monit; 1989; 11(2):171-5. PubMed ID: 2718222
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.